Skip to main content
Clinical Trials/NL-OMON54197
NL-OMON54197
Recruiting
Not Applicable

Detection of recirculating tumor-associated tissue macrophages and circulating melanoma cells as a tool for monitoring melanoma patients: a pilot study. - MelanoScan

Immunologie0 sites2 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Melanoma
Sponsor
Immunologie
Enrollment
2
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Immunologie

Eligibility Criteria

Inclusion Criteria

  • General: • At least 18 years old • Able to understand the patient information • Diagnosed with, or a lesion high likelihood of, a cutaneous melanoma Phase 1: • Skin lesion with a diameter of \>1 cm, highly likely of melanoma or loco\-regional metastases, including local recurrences and in\-transit metastasis or hematogenic or lymphogenic metastasis. Phase 2A: • Bulky lymph node disease who undergo debulking surgery. Phase 2B: • Hematogenic or lymphogenic metastasis who undergo debulking surgery. Phase 3: • Different control groups: lichen planus, psoriasis, dermatitis, vitiligo, atopic eczema, and individuals with \>100 moles.

Exclusion Criteria

  • Immune disorders other than stated in the control groups
  • Patients undergoing systemic cytotoxic or immunosuppressant therapy
  • Uveal or mucosal melanoma
  • Anamnestic pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials